LONDON (Reuters) – AstraZeneca has signed a partnership deal with U.S. rival Eli Lilly that could earn the British company up to $500 million if a promising – but risky – experimental Alzheimer’s drug proves successful.
AstraZeneca said in May that it was looking to find a partner for its so-called BACE inhibitor drug called AZD3293, which is set to enter late-stage Phase III clinical testing against Alzheimer’s.
LONDON (Reuters) – Injecting Roche’s cancer drug Avastin as a cheap eye treatment does not appear to increase deaths or serious side effects, according to an independent study that is likely to fuel a row over the medicine’s unapproved use.
An analysis of nine clinical trials – including three unpublished ones – concluded that health policies favoring the much more expensive eye drug Lucentis over Avastin were not supported by current evidence.
LONDON, Sept 12 (Reuters) – New European Commission
President Jean-Claude Juncker came under fire from health
campaigners on Friday for his plan to shift responsibility for
medicines to the Commission’s industrial division from health.
Juncker announced earlier this week the proposal to move the
supervision of medicines and health technology from the
directorate general (DG) for Health and Consumers to the DG for
Enterprise and Industry as part of a broad reallocation of
LONDON (Reuters) – A new nicotine inhaler to be sold by a unit of British American Tobacco has been licensed in the UK as a medicinal product, marking the arrival of a novel alternative in the fast-growing market for electronic cigarettes.
The cigarette-shaped Voke Inhaler marks a further move by one of the world’s biggest tobacco companies to defend its turf in a rapidly changing market. Since it involves no heat, electronics or battery it is not classified as an e-cigarette.